Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
Tantry U, Raghavakurup L, Becker R, Singh S, Bliden K, Gurbel P. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome. Expert Opinion On Pharmacotherapy 2024, 25: 1271-1280. PMID: 39072402, DOI: 10.1080/14656566.2024.2385062.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary syndromeElevated risk of bleedingPathological thrombosisTreatment of acute coronary syndromesClinical thrombotic eventsPhysiological hemostasisRisk of bleedingPrevention of thrombosisFXIa inhibitorsBleeding riskReceptor blockersThrombotic eventsAntiplatelet therapyPlatelet antagonistsAntithrombotic efficacyFXIa inhibitionThrombosisExperimental thrombosisPatientsElevated riskLiterature searchAnticoagulationLarge-scale studiesFXIaFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 1-14. PMID: 38622277, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trials